Research article · 1 Jun 2011
Conference proceedingPublished Aug 2020
Open access literature databases for mandatory drug safety literature screening during clinical development and post market – equal access to new science for pharmaceutical companies.
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Statement of the Problem: It is difficult and expensive to meet the regulatory requirements in Europe and USA using existing commercial providers. Regulatory agencies mandate frequent often weekly literature searches using widely used reference databases. In addition, the European Union require literature searches in local language in member states. For many small or midsize pharmaceutical companies, the current costs for access to commercial reference databases and articles is prohibitive. Methodology & Theoretical Orientation: To conduct the required literature searches normally a subscription is required to access to commercial databases where the cost can run tens of thousands annually. Access to the full text articles must be paid separately which typically cost between $20-100 to access pr. article. Most existing library databases are not designed to support the specialized type of search that is required for drug safety to produce expedited single case reports and aggregate reports where searches are in date sequence and articles should be presented in a tabular format to quickly review the relevance of the article and access the full text as needed.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Short communication · 20 Jul 2020
Open access pharmacovigilance databases: Analysis of 11 databases
Conference abstract · 6 Jul 2017
Open access pharmacovigilance databases: Analysis of 11 databases
Short communication · 1 Aug 2020
Pharmacovigilance 2020: Pancreatic and Thyroid Cancer Related to Exenatide and Liraglutide Treatment: A Post-marketing Analysis of Spontaneous Cases Reported in EudraVigilance Database-Ghanshyam MaliSun Pharmaceutical Industries Ltd.
Editorial · 30 May 2020
Editorial Note for Journal of Pharmaceutical Regulatory Affairs: Open Access
More from this journal
The newest in Journal of Pharmacokinetics & Experimental Therapeutics.
Editorial · 31 Jan 2025
Molecular Pharmacokinetics: Mechanisms of Drug Absorption, Distribution, Metabolism, and Excretion
Editorial · 31 Jan 2025
Integrating Pharmacokinetics in the Early Stages of Drug Design: Principles, Challenges, and Applications
Editorial · 31 Jan 2025
Innovative Strategies in Experimental Therapeutics: Advancements in Drug Discovery and Development
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Pharmacokinetics & Experimental Therapeutics
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Steen Ottosen”